Beijing Kangerfu Pharmaceutical Co., Ltd.

To explore the pharmacokinetic and material balance characteristics of icariin soft capsules in healthy subjects after oral administration.

Primary study objective: To evaluate the bioequivalence of single fasting and single postprandial administration of calcium dobesilate tablets 0.25 g (specification: 0.25 g/tablet; test preparation) produced by Ningxia Kangya Pharmaceutical Co., Ltd. and calcium dobesilate tablets 250 mg (trade name: Doxium; specification: 250 mg/tablet; reference preparation) produced by OM pharma S.A. in healthy Chinese subjects; Secondary study objective: To observe the safety of the test preparation and the reference preparation in healthy subjects.

In healthy subjects, the absorption rate and extent of Saxagliptin Metformin Sustained-Release Tablets (I) developed by Beijing Kangerfu Pharmaceutical Co., Ltd. were studied under fasting and postprandial conditions, using Saxagliptin Metformin Sustained-Release Tablets (I) owned by AstraZeneca AB as the reference preparation, and the bioequivalence of the test preparation and the reference preparation was evaluated. The safety of the test preparation and the reference preparation when taken orally in healthy subjects was observed.